SR-4835 是一种 ATP 竞争性的CDK12/CDK13高选择性抑制剂。它与破坏 DNA 的化学疗法和 PARP 抑制剂协同作用，并引起三阴性乳腺癌细胞凋亡。

SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (TNBC) cells

2387704-62-1

C21H20Cl2N10O

499.36

SR-4835

DMSO:5 mg/mL (10.01 mM),ultrasonic and warming and heat to 60°C
Powder: -20°C for 3 years
In solvent: -80°C for 2 years